Annual “EP Vantage 2017 Preview” report discusses what’s in store for biopharma in the coming year
LONDON, BOSTON, SAN FRANCISCO, TOKYO (December 8, 2016) – Despite the uncertainty that loomed over the pharma and biotech sectors with unexpected outcomes from both the US presidential election and UK’s vote to leave the EU, 2017 may bring renewed energy to the industry with potential for more corporate activity and cash flow.
According to EP Vantage, the editorial branch of the market intelligence firm Evaluate Ltd, the Trump victory may lead to a slew of business-friendly initiatives, based on the predicted lessening of political scrutiny towards drug pricing. The report shows that although the issue of drug pricing is not going away, 2017 will start with a flush of new confidence for investors, and a possible uptick in mergers and acquisitions.
According to the “EP Vantage 2017 Preview” report, 2017 will see:
“With a pro-business administration established in the world’s biggest drugs market, equity analysts and investors are adopting an optimistic outlook for the pharmaceuticals industry in 2017, and predict benefits for biotechnology stocks,” said Lisa Urquhart, EP Vantage Editor. “On the flip side, the failure of Eli Lilly’s Alzheimer’s disease project solanezumab, this November, is a staunch reminder of the inherent risk in drug development -- and the dangers of overblown expectations.”
For more details, please view the complimentary EP Vantage 2017 Preview report based on market intelligence from EvaluatePharma®. It can be downloaded at: www.evaluategroup.com/PharmaBiotech2017Preview.
About Evaluate Ltd
Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2022 for commercial teams and their advisors within the global life science industry. We help our clients make high value decisions through superior quality, timely, must-have data and insights, combined with personalised, expert client support. Our online subscription services cover the pharmaceutical, biotech and medtech sectors. Our Custom Services group delivers project based analytical and data services. EP Vantage, our independent, award-winning editorial team, offers data-driven, forward-looking news, commentary and analysis on a daily basis. For more information please visit: www.evaluategroup.com. On Twitter: @evaluatepharma, @evaluatemedtech, @evaluateJP, @epclinicaltrial, @epvantage.
Issued for and on behalf of Evaluate Limited by Instinctif Partners.
For more information please contact: firstname.lastname@example.org.
Melanie Toyne-SewellManaging Partner